z-logo
open-access-imgOpen Access
Primary cutaneous CD8+CD30+anaplastic large cell lymphoma: An unusual case with a high Ki-67 index-A short review
Author(s) -
Jitendra G Nasit,
Shivani Patel
Publication year - 2015
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.160483
Subject(s) - mycosis fungoides , medicine , lymphomatoid papulosis , cd30 , cd8 , lymphoproliferative disorders , lymphoma , pathology , anaplastic large cell lymphoma , brentuximab vedotin , cytotoxic t cell , dermatology , immunology , antigen , biology , biochemistry , in vitro
Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a part of the spectrum of CD30(+) cutaneous lymphoproliferative disorder, characterized by variable degrees of CD2, CD3, CD4 and CD5 expression by lymphoid cells. PCALCLs with an expression of cytotoxic phenotype (CD8(+)) and cytotoxic proteins are uncommon. Cutaneous CD8(+) CD30(+) lymphoproliferative lesions are difficult to classify, diagnose and may be the cause of misdiagnose. CD8(+) PCALCL must be distinguished from CD8(+) mycosis fungoides, lymphomatoid papulosis type D and primary cutaneous aggressive epidermotropic CD8(+) T-cell lymphoma. Usually CD8(+) PCALCL is an indolent disease with a favorable prognosis, except few cases can show poor outcomes. The high Ki-67 index points toward advanced PCALCL. Treatment modalities include surgical excision, radiotherapy and clinical monitoring. Chemotherapy is reserved for disseminated disease. We report a 59-year-old male presented with rapid development of multiple painful reddish-brown plaques and nodular ulcerative skin lesions over the left thigh region since 2 months. A diagnosis of CD8(+) PCALCL with a high Ki-67 index was made on the basis of histology and immunohistochemistry, in co-relation with clinical presentation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here